甲孕酮对改善癌症患者化疗期间生活质量的临床观察

目的 为了改善癌症患者化疗期间生活质量,方法 １９９１年１２月至１９９４年１２月期间,对３０例癌症患者进行了甲孕酮（ＭＰＡ）治疗的临床观察,设对照组３０例,结果 口服ＭＰＡ的癌症患者普遍反映精神,食欲好转,体重有所增加,生活质量综合指数ＫＰＳ评分较好治疗明显提高（８０％对照组为３６．７％,Ｐ〈０．０１）,伴有痛疼的患者（计１８例）的癌痛改善治疗组８３．３％显著高于对照组的４１％,结论 甲孕酮（ＭＰ     

醋酸甲孕酮改善癌症患者化疗期间生活质量的临床研究

目的 观察患者口服250mg醋酸甲孕酮改善化疗期间生活质量。方法 108例各种肿瘤患者,随机分成两组,治疗组化疗期间采用甲孕酮250mg,每日3次口服,8周为一观察周期,对照组采用单独化疗。结果 治疗组中,转移灶控制率（11.1%),疼痛缓解率（29.6%),食欲增加（38.9%),体重增加（46.3%),骨髓保护较理想,与单独化疗组相比较,取得了满意的疗效。结论 250mg甲孕酮能有效改善癌症患者化疗期间的食欲,增加体重,缓解疼痛。     

甲孕酮对乳腺癌患者化疗期间生活质量的影响

目的评价甲孕酮对乳腺癌患者化疗期间生活质量的影响.方法对62例住院化疗的乳腺癌患者随机分为甲孕酮(MPA)组和对照组(服淀粉片),根据KPS评分进行双盲回顾性分析.结果MPA组综合指数KPS评分(86.7%)较对照组(33.3%)明显提高(p＜0.01);伴有骨转移的晚期患者癌痛缓解率,治疗组为83.3%,对照组为50%.结论甲孕酮可显著改善乳腺癌患者化疗期间的生活质量.     

甲孕酮对乳腺癌患者化疗期间生活质量的影响

目的:评价甲孕酮对乳腺癌患者化疗期间生活质量的影响.方法:对62例住院化疗的乳腺癌患者随机分为甲孕酮(MPA)组和对照组(服淀粉片),根据KPS评分进行双盲回顾性分析.结果:MPA组综合指数KPS评分(86.7%)较对照组(33.3%)明显提高(p＜0.01);伴有骨转移的晚期患者癌痛缓解率,治疗组为83.3%,对照组为50%.结论:甲孕酮可显著改善乳腺癌患者化疗期间的生活质量.     

甲孕酮改善晚期肿瘤病人化疗期生活质量

目的　观察病人服用甲孕酮后改善化疗引起的厌食、体重下降、Kps评分下降、骨髓抑制及胃肠道反应的作用。方法　 117例接受化疗的晚期肿瘤患者 ,采用单盲随机分成化疗 +甲孕酮组共 5 8例 ,单用化疗组 5 9例作为对照。结果　在化疗 +甲孕酮治疗的 15 6个周期中有 5 5 .1%食量增加 ;42 .3 %体重增加 ;平均每周期体重增加 1.46± 0 .82kg ;血浆白蛋白升高 2 .1± 3 .3 0 g/L ;2 6.9%Kps评分改善。按WHO抗癌药物急性毒性分级标准 ,3 1.4%出现Ⅱ度以上的白细胞下降、血红蛋白下降 2 3 .7%、胃肠道反应 17.9% ,平均恢复时间分别为 5 .8± 5 .5天、5 .9± 3 .8天及 1.8± 1.4天。上述各项指标与对照组比较均有显著性差异。结论　甲孕酮如能正确合理地应用于晚期肿瘤病人的辅助治疗 ,可以全面改善化疗期癌症患者的生活质量。     

甲孕酮合并化疗改善晚期肺癌患者的生活质量

目的 :观察患者服用甲孕酮后改善化疗所致的厌食、体重下降、ECOG下降、骨髓抑制及胃肠道反应的作用 ,同时观察甲孕酮对晚期癌症的止痛作用及促进蛋白同化作用。方法 :130例接受化疗的晚期肺癌患者 ,采用单盲随机分成单用化疗组及化疗 甲孕酮组。结果 :在化疗 甲孕酮组治疗的160个周期中有43 1 %食量增加 ;45%体重增长 ;平均每周期体重增加0 74±1 56kg;血浆白蛋白升高1 2±2 9g/L ;88 1 %疼痛减轻及28 1 ?OG改善。化疗的毒副作用按WHO抗癌药物急性毒性分级标准 ,出现Ⅱ度以上的白细胞下降33 8%、血红蛋白下降15 6 %及胃肠道反应18 1 % ,平均恢复时间分别为6 4±4 6天、5 3±4 1天及1 89±1 2天。以上各项指标与单用化疗组相比均有显著性差异。结论 :甲孕酮如能正确合理地用于晚期癌症的治疗 ,可以全面改善化疗期癌症患者的生活质量     

甲孕酮合并化疗改善晚期胃癌病人的生活质量

目的：通过甲孕酮与化疗并用的方法，探讨晚期胃癌化疗中改善生活质量的有效措施。方法：采用甲孕酮与EDF化疗方案联合应用，并以单纯EDF方案化疗作为对照组进行临床研究，通过观察分析治疗组和对照组之间的生活质量差异评价治疗效果。结果：化疗甲孕酮组的化疗后的进食量增加77.1％（37/48），无变化占22.9％（11/48），无一例食欲减退；而单纯化疗组化疗后食欲减退为58.3％（28/48），无变化41.7％（20/48），无食欲增加病例。化疗加甲孕酮组化疗后体重增加、无变化、减少分别为35.4％（17/48），54.2％（26/48）和10.4％（5/48）；单纯化疗组则分别为4.2％（9.2/48）、35.4％（17/48）和60.4％（29/48）。上述结果均有显著性差异。结论：甲孕酮与化疗并用，能够显著改善晚期胃癌病人化疗后的生活质量，对树立病人的信心，提高病人对化疗的承受能力和提高化疗效果具有重要应用价值。     

甲孕酮合并化疗改善晚期肺癌患者的生活质量

目的观察晚期肺癌患者服用甲孕酮后化疗毒副反应改善情况,及止痛和促进蛋白同化作用。方法130例接受化疗的晚期肺癌患者采用单盲法随即分成单用化疗组及化疗+甲孕酮组。结果在化疗+甲孕酮组治疗的160个周期中43.1％患者食量增加,45％体重增长,平均每周期体重增加0.74±1.56 kg,血浆白蛋白升高1.2±2.9g/L。88.1％患者疼痛减轻,28.1％ECOG评分改善。化疗的毒副反应按WHO抗癌药物急性毒性分级标准,Ⅱ度以上白细胞下降发生率为33.8％,血红蛋白下降15.6％,胃肠道反应18.1％,平均恢复时间分别为6.4±4.6、5.3±4.1及1.89±1.2 d。以上各项指标与单用化疗组相比差异均有显著性。结论 甲孕酮如能正确合理地用于晚期癌症的治疗,可以全面改善化疗期间癌症患者的生活质量。     

甲孕酮改善化疗病人厌食的临床观察

目的 改善化疗病人的厌食。方法 １９９６年１２月￣１９９８年１２月期间,对３０例化疗患者进行甲孕酮（ＭＰＡ）治疗,剂量３００ｍｇ,每日３次,持续口服３０天。设对照组３０例。结果 口服甲孕酮的患者食欲不减或增加,占７６．７％。而对照组中仅２０％的患者食欲不减少（Ｐ〈０．０１）。结论 甲孕酮可以显著改善化疗病人的厌食和食欲不振。     

甲孕酮合并化疗改善晚期胃癌病人的生活质量

目的　通过甲孕酮与化疗并用的方法 ,探讨晚期胃癌化疗中改善生活质量的有效措施。方法　采用甲孕酮与EDF化疗方案联合应用 ,并以单纯EDF方案化疗作为对照组进行临床研究 ,通过观察分析治疗组和对照组之间的生活质量差异评价治疗效果。结果　化疗甲孕酮组的化疗后的进食量增加占 77 1% ( 3 7/ 4 8) ,无变化占 2 2 9% ( 11/ 4 8) ,无一例食欲减退 ;而单纯化疗组化疗后食欲减退为 5 8 3 % ( 2 8/ 4 8) ,无变化 41 7% ( 2 0 / 4 8) ,无食欲增加病例。化疗加甲孕酮组化疗后体重增加、无变化、减少分别为 3 5 4%( 17/ 4 8) ,5 4 2 % ( 2 6/ 4 8)和 10 4% ( 5 / 4 8) ;单纯化疗组则分别为 4 2 % 92 / 4 8)、3 5 4% ( 17/ 4 8)和 60 4% ( 2 9/ 4 8)。上述结果均有显著性差异。结论　甲孕酮与化疗并用 ,能够显著改善晚期胃癌病人化疗后的生活质量 ,对树立病人的信心 ,提高病人对化疗的承受能力和提高化疗效果具有重要应用价值     

醋酸甲地孕酮联合化疗改善晚期肺癌患者的生活质量

目的 观察醋酸甲地孕酮合并化疗对晚期肺癌患者的生活质量影响.方法 甲地孕酮联合化疗作为治疗组,单纯化疗作为对照组进行临床研究,观察两组治疗前后进食、体重、Karnofsky评分变化.结果 治疗组中食欲改善占93.8%,体重增加率72.9%,Karnofsky分值提高66.7%,明显优于对照组(P＜0.01).结论 醋酸甲地孕酮联合化疗能显著改善晚期肺癌患者生活质量,且毒副反应较轻.     

甲孕酮伍用止吐药预防化疗引起的恶心呕吐

 止吐药已基本能控制化疗呕吐，但化疗引起的食欲不振和恶心尚末引起充分注意。本文旨在观察甲孕酮与胃复安、地塞米松联合应用是否可进一步减轻这些化疗反应。结果表明，加用甲孕酮的病人，63%末出现恶心，而对照组仅29%（P<0.05）；对预防化疗引起的呕吐有一定增强效果，但无统计学意义；对食欲的保护最为明显，化疗期间及化疗后食欲不减或有所增加者占73%，对照组仅19%（P<0.05）。即使发生食欲者，其幅度和持续时间也明显低于对照组。作者认为，甲孕酮与止吐药合用可进一步减少化疗的消化道并发症，对提高病人的生活质量、保证抗肿瘤治疗顺利进行具有重要意义。     

Quality of Life During Chemotherapy in Non-Small Cell Lung Cancer Patients

To evaluate the usefulness of chemotherapy in non-small cell lung cancer, objective response, length of remission and survival have been considered the main yardsticks. Subjective improvement and gain in Karnofsky performance status have attracted very little attention. Thirty-one patients with stages III and IV underwent combination chemotherapy with high-dose cisplatin, and were assessed with categorical scales and 100 mm visual analogue scales used by patients themselves to report on several symptoms of their illness. After chemotherapy 17 of 19 patients (89%) gained weight; 20 presented anorexia, 10 of those (50%) improved; 15 had pain, 7 of those (47%) were alleviated; cough was reported in 22, in 10 (45%) it was ameliorated; hemoptysis disappeared in 10 of 11 patients (91 %); of the 9 patients who had dyspnea, 7 improved (78%); and astenia was attenuated in 8 of 16 patients (50%). Quality of life was reported improved in 75% of those patients who had considered themselves seriously affected prior to the treatment. When compared with Karnofsky performance status, no relationship was found (r=0.31). It is concluded that, apart from the objective response achieved, a significant proportion of patients did benefit from treatment as demonstrated by a marked relief of symptoms.     

乌头注射液联合化疗的临床效果观察

目的 :探讨乌头注射液联合化疗改善癌症患者的生活质量可行性。方法 :2 6例癌症患者随机分成两组 ,乌头注射液 化疗组 15例 ,单纯化疗组 11例。结果 :乌头注射液 化疗组生活质量明显提高 ,包括体重、Karnofsky评分的提高、厌食和乏力的改善 ,其分别为 80 %、80 %、93%、6 7% ,而单纯化疗组分别为 10 %、2 7%、10 %、18% ,两者间均有统计学意义 ;疼痛缓解率也有明显提高 ,分别为 85%、4 0 % ,两者间差异有显著性 (P <0 .0 5)。     

The Impact of Chemotherapy on the Quality of Life of Breast Cancer Patients

One hundred and thirty-seven breast cancer patients, 102 receiving adjuvant chemotherapy and 35 receiving palliative chemotherapy for metastatic disease underwent a 37-item quality-of-life questionnaire to evaluate the impact of disease and treatment on physical, psychological and social well being. Patient groups were designated as follows — Adj CT: patients undergoing the questionnaire during their adjuvant chemotherapy program; Post Adj CT: patients evaluated 3 to 8 months after termination of adjuvant chemotherapy; Mts CT: patients assessed during palliative chemotherapy for metastatic disease, and Post Mts CT: patients 3 to 8 months after termination of palliative chemotherapy. Physical and social activities were reported as unaltered or normal by 64 to 70% and 52 to 67% of patients, respectively. Psychological status was judged normal by 39 to 45% of patients. No significant differences were observed between the patient groups. In 83 to 90% of cases the patient normally took care of herself. In 62 to 87% of cases time dedicated to recreational activities was reported as unaltered. The majority of patients (84%) judged that their relationship with partner and/or family were good. Severe anxiety was reported in 19 to 28% of patients and severe depression was infrequent (3.9%). Information regarding disease and treatment given by health professionals was considered satisfactory by 80 to 100% of patients. This pilot experience indicates that the majority of breast cancer patients respond normally to the stresses of both adjuvant and palliative chemotherapy; quality of life does not appear to improve 3-8 months after termination of chemotherapy; family support is good in the majority of cases and that a subset of patients with severe anxiety who could benefit from pharmacological and/or psychological intervention can be identified.     

Changes in Hematologic Parameters during Treatment with Medroxyprogesterone Acetate for Breast Cancer

To elucidate the etiology of the thrombogenic effects of high-dose medroxyprogesterone acetate (MPA) in the treatment of breast cancer, hematologic parameters were sequentially assessed in 12 patients receiving MPA 800 mg p.o. daily for 6 months as adjuvant hormone therapy after mastectomy. The results were as follows. (1) Coagulation system: levels of factor VII and fibrinogen decreased significantly, whereas factors II and IX increased significantly, with a shortened activated partial thromboplastin time. (2) Fibrinolytic system: plasminogen and α₂-lasmin inhibitor-plasmin complex increased, whereas fibrinogen degradation products remained low. (3) Anticoagulation system: antithrombin III increased significantly. (4) These changes were most marked after 2 or 4 weeks of MPA treatment, and returned to the pretreatment level one month after discontinuation of treatment. (5) No patients in this study developed thromboembolic disease during or after MPA administration. These results indicate that MPA may induce a hypercoagulable state, but this state does not directly lead to the development of thrombosis.     

醋酸甲地孕酮联合化疗治疗晚期胃癌疗效观察

目的 观察醋酸甲地孕酮对接受化疗的晚期胃癌患者生活质量的改善作用.方法 38例晚期胃癌患者分为治疗组和对照组.对照组18例采用常规化疗方法治疗;治疗组20例在化疗基础上加用醋酸甲地孕酮.观察2组患者生活质量改善状况及毒副反应.结果 治疗组较对照组生活质量有明显改善（P〈0.05）;胃肠道反应、骨髓抑制等毒副反应减轻（P〈0.05）.结论 醋酸甲地孕酮联合化疗能有效改善晚期胃癌患者生活质量,减轻化疗毒副反应.